Additional file 4: of Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis Eduardo Castañón Christian Rolfo David Viñal Inés López Juan Fusco Marta Santisteban Patricia Martin Leire Zubiri José Echeveste Ignacio Gil-Bazo 10.6084/m9.figshare.c.3623249_D3.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_of_Impact_of_epidermal_growth_factor_receptor_EGFR_activating_mutations_and_their_targeted_treatment_in_the_prognosis_of_stage_IV_non-small_cell_lung_cancer_NSCLC_patients_harboring_liver_metastasis/4400564 Table S4. Univariate Regression Model for predicting OS (overall survival) in our clinical series. 2015-08-07 05:00:00 Liver metastasis Non-small cell lung cancer (NSCLC) Epidermal growth factor receptor (EGFR) EGFR tyrosin-kinase inhibitors Prognosis